9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof

Patent metadata

Field	Value
Publication number	US-11098057-B2
Application number	US-201816494722-A
Country	US
Kind code	B2
Filing date	Mar 15, 2018
Priority date	Mar 16, 2017
Publication date	Aug 24, 2021
Grant date	Aug 24, 2021

Abstract

The present invention provides compounds, compositions thereof, and methods of using the same.

First claim

We claim:

1. A compound of formula XX:

or a pharmaceutically acceptable salt thereof, wherein:
T is —NH— or —O—;
R is hydrogen or an optionally substituted C 1-6 aliphatic;
R 1 is methyl;
R 2 is halogen, —CN, —SR y , —S(O) 2 R y , —SO 2 R y , —OSO 2 R y , —OC(O)R y , or —OP(O) 2 OR y ; and
each R y is independently selected from optionally substituted C 1-6 aliphatic or optionally substituted phenyl.

2. The compound according to claim 1 , wherein T is —O—.

3. The compound according to claim 1 , wherein T is —NH—.

4. The compound according to claim 1 , wherein R 2 is halogen.

5. The compound according to claim 1 , wherein R 2 is —SR y or —SO 2 R y .

6. A pharmaceutically acceptable composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

7. The compound according to claim 4 , wherein R 2 is fluoro or chloro.

8. The compound according to claim 4 , wherein R 2 is chloro.

9. The compound according to claim 2 , wherein R 2 is chloro.

10. The compound according to claim 1 , wherein R is C 1-6 aliphatic substituted with oxo, halogen, —CN, (CH 2 ) 0-4 R ∘ , —(CH 2 ) 0-4 OR ∘ , or —(CH 2 ) 0-4 S(O) 2 R ∘ , wherein R ∘ is C 1- 6 aliphatic.

11. The compound according to claim 9 , wherein R is C 1-6 aliphatic substituted with oxo, halogen, —CN, —(CH 2 ) 0-4 R ∘ , —(CH 2 ) 0-4 OR ∘ , or —(CH 2 ) 0-4 S(O) 2 R ∘ , wherein R ∘ is C 1-6 aliphatic.

12. The compound according to claim 1 , wherein the compound is selected from:

or a pharmaceutically acceptable salt thereof.

13. The compound according to claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

14. A pharmaceutically acceptable composition comprising the compound according to claim 11 and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

15. A pharmaceutically acceptable composition comprising the compound according to claim 12 and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

Assignees

• Celgene Car Llc

Inventors

• Malona John
• Ruchelman Alexander L

Classifications

• C12Y207/11024

  Mitogen-activated protein kinase (2.7.11.24), i.e. MAPK or MAPK2 or c-Jun N-terminal kinase · CPC title

• C07D495/14 Primary

  Ortho-condensed systems · CPC title

• C12N9/12 Primary

  transferring phosphorus containing groups, e.g. kinases (2.7) · CPC title